Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
This is a preclinical materials science study reporting rational design and in vitro/in vivo characterization of a nanoagent; it raises mechanistic questions about nanoparticle performance but does not test efficacy against a comparator in any clinical or disease model.
Early-stage in vitro work demonstrating proof-of-concept for a nanotheranostic platform in cell models; no animal or clinical data reported, and efficacy claims are based on cultured TNBC cells without in vivo validation or comparative clinical outcomes.
Early-stage preclinical and patient-derived organoid study of a novel nanoplatform with promising mechanistic data but no clinical trial evidence and reliance on mouse models for efficacy claims.